0001567619-18-002684.txt : 20180914 0001567619-18-002684.hdr.sgml : 20180914 20180914192916 ACCESSION NUMBER: 0001567619-18-002684 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180912 FILED AS OF DATE: 20180914 DATE AS OF CHANGE: 20180914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Templeman Blaine CENTRAL INDEX KEY: 0001653641 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 181072184 MAIL ADDRESS: STREET 1: C/O ADURO BIOTECH, INC. STREET 2: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ADURO BIOTECH, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 510-848-4400 MAIL ADDRESS: STREET 1: 740 HEINZ AVENUE CITY: BERKELEY STATE: CA ZIP: 94710 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc1.xml FORM 4 X0306 4 2018-09-12 0 0001435049 ADURO BIOTECH, INC. ADRO 0001653641 Templeman Blaine C/O ADURO BIOTECH, INC. 740 HEINZ AVENUE BERKELEY CA 94710 0 1 0 0 Executive VP, General Counsel Common Stock 2018-09-12 4 A 0 77500 0.00 A 147437 D Common Stock 2018-09-13 4 S 0 6056 6.4993 D 141381 D Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018. The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Jennifer Lew, Attorney-in-Fact 2018-09-14